In a report released today, Ryan Langston from TD Cowen maintained a Buy rating on Tenet Healthcare, with a price target of $192.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Langston’s rating is based on Tenet Healthcare’s strong financial performance and strategic positioning. The company delivered a significant EBITDA beat and increased its EBITDA guidance, which indicates robust operational efficiency and effective management strategies. Despite a slight reduction in adjusted admissions guidance, the overall financial outlook remains positive, with strong same-store growth and a favorable payor mix contributing to the company’s success.
Additionally, Tenet Healthcare’s hospital segment has shown resilience with improved margins due to effective expense management and productivity gains. The company’s revenue cycle management capabilities have also enhanced cash flow and reduced friction in a challenging payor environment. These factors, combined with the company’s advocacy for policy extensions that could benefit its operations, support Ryan Langston’s Buy rating for Tenet Healthcare’s stock.
In another report released today, Wells Fargo also maintained a Buy rating on the stock with a $195.00 price target.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of THC in relation to earlier this year.